HC
REPL icon

Hurley Capital’s Replimune Group REPL Stock Holding History

Hurley Capital’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.34K Sell
482
-163
-25% -$997 ﹤0.01% 422
2026
Q1 		$4.93K Buy
+645
New +$4.93K ﹤0.01% 438
2025
Q4 		– Sell
-1,000
Closed -$4.19K – 725
2025
Q3 		$4.19K Buy
+1,000
New +$6.39K ﹤0.01% 468

Other funds holding REPL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Hurley Capital's REPL Position: Q2 2026 in Review

Hurley Capital reduced its Replimune Group (REPL) stake by 25% in Q2 2026, selling an estimated $997 and leaving 482 shares worth $5.34K. The position accounts for ﹤0.01% of the portfolio, ranked #422.

Hurley Capital first reported a position in REPL in Q3 2025 and has held it in 3 quarters since. 199 funds tracked by Wall St. Rank hold REPL as of Q2 2026.

  • Hurley Capital held 482 shares of Replimune Group worth $5.34K as of Q2 2026.
  • Hurley Capital sold 163 Replimune Group shares in Q2 2026, an estimated $997.
  • Replimune Group made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #422 holding.
  • Hurley Capital first reported a position in Replimune Group in Q3 2025 and has held it in 3 quarters since.
  • 199 funds tracked by Wall St. Rank held Replimune Group as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.